- Home
- CTRN vs PBYI Comparison
CTRN vs PBYI Comparison
Compare CTRN & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRN
- PBYI
- Stock Information
- Founded
- CTRN 1946
- PBYI 2010
- Country
- CTRN United States
- PBYI United States
- Employees
- CTRN N/A
- PBYI N/A
- Industry
- CTRN Clothing/Shoe/Accessory Stores
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- CTRN Consumer Discretionary
- PBYI Health Care
- Exchange
- CTRN Nasdaq
- PBYI Nasdaq
- Market Cap
- CTRN 270.0M
- PBYI 237.2M
- IPO Year
- CTRN 2005
- PBYI N/A
- Fundamental
- Price
- CTRN $35.89
- PBYI $5.14
- Analyst Decision
- CTRN Buy
- PBYI Strong Buy
- Analyst Count
- CTRN 2
- PBYI 1
- Target Price
- CTRN $31.50
- PBYI $7.00
- AVG Volume (30 Days)
- CTRN 87.5K
- PBYI 489.2K
- Earning Date
- CTRN 12-02-2025
- PBYI 11-06-2025
- Dividend Yield
- CTRN N/A
- PBYI N/A
- EPS Growth
- CTRN N/A
- PBYI 434.29
- EPS
- CTRN N/A
- PBYI 0.97
- Revenue
- CTRN $782,716,000.00
- PBYI $238,062,000.00
- Revenue This Year
- CTRN $8.16
- PBYI N/A
- Revenue Next Year
- CTRN $5.38
- PBYI N/A
- P/E Ratio
- CTRN N/A
- PBYI $5.32
- Revenue Growth
- CTRN 3.32
- PBYI 8.63
- 52 Week Low
- CTRN $16.18
- PBYI $2.32
- 52 Week High
- CTRN $39.37
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- CTRN 58.32
- PBYI 53.66
- Support Level
- CTRN $35.12
- PBYI $5.11
- Resistance Level
- CTRN $36.90
- PBYI $5.59
- Average True Range (ATR)
- CTRN 1.77
- PBYI 0.26
- MACD
- CTRN 0.25
- PBYI 0.01
- Stochastic Oscillator
- CTRN 74.80
- PBYI 47.64
About CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.